Medicine

Lessons from an unfavorable genetics therapy trial for Duchenne muscle dystrophy

.Nature Medication, Released online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec got FDA authorization after an unfavorable test, which highlights the many complexities and also difficulties of drug progression in this particular setup.